Fig. 2From: Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial groupCONSORT diagram summarizing the number of subjects who were screened, enrolled, and randomized to the three treatment arms. In addition, the subject outcomes are provided at the completion of the 6 month Treatment Period and after 6 and 12 months of observation following the Treatment PeriodBack to article page